Furthermore, genetic variations within this pathway, such as mutations in AKT and TSC1, have been associated with differential responses to chemotherapy in NSCLC patients, suggesting that the LKB1/AMPK/mTOR axis may also impact treatment outcomes [39,40]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.